Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
SAN RAFAEL, Calif., Jan. 28, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 25, at 4:30 p.m. ET to discuss fourth quarter and full year 2015 financial results and provide a general business update.
Dial-in Number
U.S. / Canada Dial-in Number: (877) 303-6313
International Dial-in Number: (631) 813-4734
Conference ID: 34535772
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 34535772
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
